Literature DB >> 27347331

Sesamin protects against renal ischemia reperfusion injury by promoting CD39-adenosine-A2AR signal pathway in mice.

Ke Li1, Xia Gong2, Ge Kuang3, Rong Jiang4, Jingyuan Wan3, Bin Wang1.   

Abstract

Ischemia reperfusion injury (IRI) is a leading cause of acute kidney injury with high morbidity and mortality due to limited therapy. Here, we examine whether sesamin attenuates renal IRI in an animal model and explore the underlying mechanisms. Male mice were subjected to right renal ischemia for 30 min followed by reperfusion for 24 h with sesamin (100 mg/kg) during which the left kidney was removed. Renal damage and function were assessed subsequently. The results showed that sesamin reduced kidney ischemia reperfusion injury, as assessed by decreased serum creatinine (Scr) and Blood urea nitrogen (BUN), alleviated tubular damage and apoptosis. In addition, sesamin inhibited neutrophils infiltration and pro-inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-1β production in IR-preformed kidney. Notably, sesamin promoted the expression of CD39, A2A adenosine receptor (A2AAR), and A2BAR mRNA and protein as well as adenosine production. Furthermore, CD39 inhibitor or A2AR antagonist abolished partly the protection of sesamin in kidney IRI. In conclusion, sesamin could effectively protect kidney from IRI by inhibiting inflammatory responses, which might be associated with promoting the adenosine-CD39-A2AR signaling pathway.

Entities:  

Keywords:  A2 adenosine receptors (A2AR); CD39; Renal ischemia reperfusion injury; adenosine; sesamin

Year:  2016        PMID: 27347331      PMCID: PMC4891436     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  39 in total

1.  Simultaneous determination of adenosine, S-adenosylhomocysteine and S-adenosylmethionine in biological samples using solid-phase extraction and high-performance liquid chromatography.

Authors:  U Delabar; D Kloor; G Luippold; B Mühlbauer
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1999-03-19

Review 2.  Inflammation in acute kidney injury.

Authors:  Gilbert R Kinsey; Li Li; Mark D Okusa
Journal:  Nephron Exp Nephrol       Date:  2008-09-18

Review 3.  A(2A) adenosine receptor: a novel therapeutic target in renal disease.

Authors:  Mark D Okusa
Journal:  Am J Physiol Renal Physiol       Date:  2002-01

4.  Sesamin ameliorates lipopolysaccharide/d-galactosamine-induced fulminant hepatic failure by suppression of Toll-like receptor 4 signaling in mice.

Authors:  Li Ma; Xia Gong; Ge Kuang; Rong Jiang; Rongchun Chen; Jingyuan Wan
Journal:  Biochem Biophys Res Commun       Date:  2015-04-09       Impact factor: 3.575

Review 5.  Adenosine and protection from acute kidney injury.

Authors:  Steven C Yap; H Thomas Lee
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

6.  Protective role of ecto-5'-nucleotidase (CD73) in renal ischemia.

Authors:  Almut Grenz; Hua Zhang; Tobias Eckle; Michel Mittelbronn; Manfred Wehrmann; Christoph Köhle; Doris Kloor; Linda F Thompson; Hartmut Osswald; Holger K Eltzschig
Journal:  J Am Soc Nephrol       Date:  2007-01-31       Impact factor: 10.121

7.  Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine.

Authors:  S Suzuki; L H Toledo-Pereyra; F J Rodriguez; D Cejalvo
Journal:  Transplantation       Date:  1993-06       Impact factor: 4.939

Review 8.  Acute renal failure: definitions, diagnosis, pathogenesis, and therapy.

Authors:  Robert W Schrier; Wei Wang; Brian Poole; Amit Mitra
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury.

Authors:  Almut Grenz; Hua Zhang; Marina Hermes; Tobias Eckle; Karin Klingel; Dan Yang Huang; Christa E Müller; Simon C Robson; Hartmut Osswald; Holger K Eltzschig
Journal:  FASEB J       Date:  2007-04-18       Impact factor: 5.191

10.  Adenosine 2B Receptor Activation Reduces Myocardial Reperfusion Injury by Promoting Anti-Inflammatory Macrophages Differentiation via PI3K/Akt Pathway.

Authors:  Yikui Tian; Bryan A Piras; Irving L Kron; Brent A French; Zequan Yang
Journal:  Oxid Med Cell Longev       Date:  2015-06-16       Impact factor: 6.543

View more
  6 in total

Review 1.  Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.

Authors:  Karen M Dwyer; Bellamkonda K Kishore; Simon C Robson
Journal:  Nat Rev Nephrol       Date:  2020-07-08       Impact factor: 28.314

2.  Neuroprotective Effect of Piclamilast-Induced Post-Ischemia Pharmacological Treatment in Mice.

Authors:  Amarjot Kaur; Thakur Gurjeet Singh; Heena Khan; Manish Kumar; Nirmal Singh; Mohamed M Abdel-Daim
Journal:  Neurochem Res       Date:  2022-04-28       Impact factor: 4.414

Review 3.  Plants with Therapeutic Potential for Ischemic Acute Kidney Injury: A Systematic Review.

Authors:  Arif Ali; Tiago Lima Sampaio; Haroon Khan; Philippe Jeandet; Esra Küpeli Akkol; Humaira Bahadar; Alice Maria Costa Martins
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-23       Impact factor: 2.650

4.  P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis.

Authors:  Laura Rennert; Stefan Zschiedrich; Lukas Sandner; Björn Hartleben; Sanja Cicko; Cemil Korcan Ayata; Charlotte Meyer; Andreas Zech; Robert Zeiser; Tobias B Huber; Marco Idzko; Florian Grahammer
Journal:  Front Immunol       Date:  2018-07-16       Impact factor: 7.561

5.  Sesamin ameliorates mucosal tissue injury of mesenteric ischemia and reperfusion in an experimental rat model.

Authors:  Mustafa B Sayhan; Serhat Oguz; Ömer Salt; Nuray Can; Taner Ozgurtas; Tulın D Yalta
Journal:  Arch Med Sci       Date:  2018-12-10       Impact factor: 3.318

6.  Sesamin Protects against and Ameliorates Rat Intestinal Ischemia/Reperfusion Injury with Involvement of Activating Nrf2/HO-1/NQO1 Signaling Pathway.

Authors:  Yilin Wang; Jin Wen; Marwan Almoiliqy; Yaojia Wang; Zhihao Liu; Xiaobo Yang; Xiaolong Lu; Qiang Meng; Jinyong Peng; Yuan Lin; Pengyuan Sun
Journal:  Oxid Med Cell Longev       Date:  2021-09-29       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.